▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #4104 by analyst upside · 2026-06-27
DNA
Ginkgo Bioworks Holdings, Inc.
Healthcare · Market Cap $670M · P/E 0x
ANALYST PRICE TARGET
-17.1%
implied upside to consensus target
Current Price $10.25
Consensus Target $8.5
Bull Target $12.0
Bear Target $5.0
Analysts Covering 2
ANALYST CONSENSUS — UNDERPERFORM
Strong Buy
0
Buy
0
Hold
0
Sell
2
52-Week Low $5.37
52-Week High $17.58
YTD Return +17.8%
FUNDAMENTALS
Market Cap $670M
P/E Ratio (TTM) N/A
Forward P/E -3.2x
EPS (TTM) $-5.38
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $151M
Profit Margin -201.1%
52-WEEK RANGE
52-Week Low $5.37
52-Week High $17.58
Current Price $10.25
Bear Target $5.0
Bull Target $12.0
● Now $10.25 ● Target $8.5
TRADING DATA
Avg Volume 1.3M
YTD Return +17.8%
Analyst Count 2
Consensus Underperform
Upside to Target -17.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Ginkgo Bioworks Holdings, Inc. (DNA) is currently trading at $10.25 with a Wall Street consensus price target of $8.5, which is 17.1% below the current price over the next 12 months. 2 analysts currently cover DNA, with a consensus rating of Underperform — 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $12.0, while the most cautious has a target of $5.0.

DNA operates in the Healthcare sector with a market capitalisation of $670M. The stock is up 17.8% year-to-date and is currently trading near the lower end of its 52-week range of $5.37 – $17.58.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

XOMA -7.5%
XOMA Royalty Corporation
$745M · P/E 26.8x · Buy
INMD -2.0%
InMode Ltd.
$841M · P/E 10.8x · Underperform
TBPH -1.3%
Theravance Biopharma, Inc.
$909M · P/E 7.9x · Hold
CYH +1.0%
Community Health Systems, Inc.
$462M · P/E 0.9x · Hold
ABUS +10.7%
Arbutus Biopharma Corporation
$905M · P/E 5.5x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DNA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG — Reiterated
Sell → Sell 2026-03-12 38% win rate (8 calls)
TD Cowen — Reiterated
Buy → Buy 2026-01-08 Building track record
BTIG — Reiterated
Sell → Sell 2025-08-25 38% win rate (8 calls)
TD Cowen — Reiterated
Buy → Buy 2024-09-20 Building track record
BTIG — Reiterated
Sell → Sell 2024-08-23 38% win rate (8 calls)
Goldman Sachs — Reiterated
Sell → Sell 2024-07-09 Building track record
BTIG — Reiterated
Sell → Sell 2024-06-26 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →